From Lab to Clinical Trials
Advancing a published cancer immunotherapy approach toward clinical testing
CIEF supports the next step in the development of a cancer immunotherapy method that has been described in peer-reviewed scientific publications.
Laboratory studies have produced promising preclinical results. The next essential step is to verify the safety and potential effectiveness of this approach in clinical trials with patients.
This transition—from laboratory research to clinical testing—is one of the most demanding stages of medical innovation.
Why This Mission Matters
Cancer remains one of the most significant medical challenges worldwide.
Scientific progress has brought important advances in diagnosis and treatment, yet many therapies remain complex, expensive, and difficult to access globally.
For this reason, continued exploration of new therapeutic approaches is essential.
The research supported by CIEF investigates an immunotherapy concept that activates natural mechanisms of the immune system against tumor cells. Preclinical experiments have demonstrated strong anti-tumor responses in laboratory models, providing a scientific basis for further investigation.
The responsible next step is clinical testing.
Scientific Foundation
The method supported by CIEF is based on a series of peer-reviewed scientific publications produced over several years of experimental research.
These studies describe the biological mechanisms of the approach and its effects in preclinical models.
While laboratory results can be encouraging, they must always be validated in carefully designed clinical trials before any conclusions about patient benefit can be made.
View the scientific publications →
The Road to Clinical Testing
Bringing a new therapeutic concept from laboratory research to clinical testing requires several critical stages.
1. Laboratory Research
The scientific basis of the method has been established through experimental research and published studies.
2. GMP Preparation
For clinical use, therapeutic components must be produced according to strict Good Manufacturing Practice (GMP) standards that ensure quality, safety, and reproducibility.
3. Regulatory and Trial Preparation
Before clinical testing can begin, the project must meet rigorous regulatory requirements and develop a carefully designed clinical study protocol.
4. Clinical Trials
Clinical trials are the only responsible way to determine whether promising preclinical findings can translate into safe and effective treatment for patients.
Each of these stages requires specialized expertise, infrastructure, and substantial financial resources.
Why Support Is Needed
The transition from laboratory discovery to clinical testing is often called the “valley of death” in biomedical research. Many promising scientific ideas never reach patients simply because this stage is extremely expensive and difficult to fund.
Large pharmaceutical programs can invest billions of euros in development. Smaller scientific initiatives, even when supported by solid research, often lack access to such resources.
CIEF was created to help bridge this gap and support the advancement of promising scientific work toward clinical validation.
How You Can Help
Progress in medical science is made possible not only by researchers and institutions but also by people who believe that promising ideas deserve a fair chance to be tested.
By supporting CIEF, you help enable the work required to move this research closer to clinical trials.
Your support contributes to:
- continued laboratory research
- preparation of GMP production
- regulatory and clinical trial preparation
Every step brings the project closer to the point where clinical testing becomes possible.
Our Commitment
CIEF is committed to transparency, scientific integrity, and responsible communication.
Clinical trials are the only way to determine whether promising laboratory findings can ultimately benefit patients. Our mission is to help create the conditions necessary for those trials to take place.